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Mitosis is a moment of exquisite vulnerability for a
metazoan cell. Failure to completemitosis accurately
can lead to aneuploidy and cancer initiation. There-
fore, if the exit from mitosis is delayed, normal cells
are usually removed by apoptosis. However, how
failure to complete mitosis activates apoptosis is still
unclear. Here, we demonstrate that a phosphory-
lated form of the BH3-only protein Bid regulates
apoptosis if mitotic exit is delayed. Bid is phospho-
rylated on serine 66 as cells enter mitosis, and this
phosphorylation is lost during the metaphase-to-
anaphase transition. Cells expressing a nonphos-
phorylatable version of Bid or a BH3-domain mutant
were resistant to mitotic-arrest-induced apoptosis.
Thus, we show that Bid phosphorylation primes cells
to undergo mitochondrial apoptosis if mitotic exit is
delayed. Avoidance of this mechanism may explain
the selective pressure for cancer cells to undergo
mitotic slippage.INTRODUCTION
During mitosis, the spindle assembly checkpoint (SAC) normally
prevents cells progressing to anaphase until all chromosomes
are correctly attached to spindle microtubules (Musacchio and
Salmon, 2007). However, if normal cells persist in mitosis for
too long, they die by apoptosis. Antimitotic drugs such as
paclitaxel keep the SAC active in order to selectively induce
apoptosis in rapidly dividing cancer cells (Sudo et al., 2004).
However, cancer cells can develop resistance to paclitaxel by
either exiting mitosis before apoptosis is initiated (termedmitotic
slippage) or by blocking the apoptotic response to delayed
mitotic exit (Rieder and Maiato, 2004). Mitotic slippage occurs
due to the degradation of cyclin B1 before apoptosis can be
activated (Gascoigne and Taylor, 2008). On the other hand,
how delayed mitotic exit activates apoptosis is poorly under-
stood, despite the possibility that activating this mechanism
could sensitize cancer cells to antimitotic drugs.The Bcl-2 family of proteins regulates apoptosis. Activation of
the Bcl-2 proteins, Bax and Bak, leads to mitochondrial outer
membrane permeabilization (MOMP) (Youle and Strasser,
2008). The BH3-only members of the Bcl-2 family either activate
Bax and Bak or inhibit antiapoptotic proteins such as Bcl-XL
and Mcl-1. Different BH3-only proteins respond to distinct
apoptotic signals and are regulated both transcriptionally and
by posttranslational modification. For example, PUMA is tran-
scriptionally upregulated by p53 (Nakano and Vousden, 2001),
whereas Bad is phosphorylated via growth factor signaling
(Gilmore et al., 2002). Another BH3-only protein, Bid, is regulated
by proteolytic cleavage by caspase-8 downstream of death re-
ceptor signaling (Gross et al., 1999; Korsmeyer et al., 2000).
Cleaved Bid then translocates to mitochondria where it activates
MOMP. However, several studies have shown that Bid can be
proapoptotic without being proteolytically cleaved (Sarig et al.,
2003; Valentijn and Gilmore, 2004).
Here, we show that Bid is phosphorylated during mitosis
within its regulatory loop. This phosphorylation sensitizes mito-
chondria for MOMP if mitotic exit is delayed. Our data suggest
that BH3 mimetics may represent a viable strategy for targeting
paclitaxel-resistant cancer cells.
RESULTS
Bid Is Required for Apoptosis following Delayed
Mitotic Exit
As mitotic cells are transcriptionally inactive, we hypothesized a
role for the posttranslationally regulated BH3-only protein, Bid,
in mitotic-arrest-induced apoptosis. To examine this, we used
two human colon carcinoma cell lines with different responses
to mitotic arrest; RKO cells undergo apoptosis, whereas DLD1
cells are prone to mitotic slippage (Figure S1A; Gascoigne and
Taylor, 2008). We knocked down endogenous human Bid
(hBid) with lentiviral small hairpin RNA (shRNA) and re-expressed
mouse Bid tagged with yellow fluorescent protein (YFP)
(mBidYFP) or YFP (Figure 1A). Bid knockdown in the RKO cells
significantly reduced the apoptotic response following arrest in
paclitaxel (Figure 1B). The response of DLD1 cells to paclitaxel
was unaffected by Bid knockdown. Furthermore, RKOcells lack-
ing hBid remained in mitosis following paclitaxel treatment,
indicating that the reduction in apoptosis was not due to mitoticCell Reports 7, 661–671, May 8, 2014 ª2014 The Authors 661
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slippage (Figures 1C and S1A). Death during mitotic arrest
showed the hallmarks of classical mitochondrial apoptosis
(Figure 1C). Furthermore, Bax//Bak/ cells were completely
resistant to paclitaxel-induced apoptosis (Figure S1B). Bid
knockdown had no effect on RKO cell proliferation (Figure S1C).
To confirm a role for Bid in apoptosis during mitotic arrest,
we generated Bid/ mouse embryonic fibroblasts (Bid/MEF)
stably expressing mBidYFP-wild-type (WT) or mBidYFP-G94E,
a substitution within the BH3 domain preventing it interacting
with multidomain Bcl-2 proteins. Again, there was no effect of
Bid expression on proliferation (Figure S1D). Paclitaxel did not
induce apoptosis in Bid/MEFs (Figure 1D). In contrast, ex-
pressing mBidYFP in Bid/MEFs led to paclitaxel sensitivity,
but this required a functional BH3 domain. The resistance of
Bid/MEFs or those expressing mBidYFP-G94E to paclitaxel
was not reverted by the BH3 mimetic, ABT-737.
These results demonstrate that, in both human carcinoma
cells and mouse fibroblasts, apoptosis caused by a paclitaxel-
induced delay in mitotic exit requires the BH3-only protein Bid.
A Unique Form of Bid Phosphorylation Occurs
during Mitosis
Bid is subject to posttranslational modifications within the loop
between a helix 2 and a helix 3 (amino acids 39–81 in the mouse
protein; Figure 2A). Following etoposide treatment, a fraction of
Bid migrated more slowly than its predominant 22 kDa form,
corresponding to phosphorylation on S61/S78 by ataxia telangi-
ectasia mutated (ATM) and ataxia telangiectasia and Rad3-
related (ATR) (Figure 2B; Kamer et al., 2005; Zinkel et al.,
2005). We noted a slower-migrating form of Bid (termed pBid)
in both untreated and etoposide-treated WT-MEFs. Both pBid
and Bid-pS61/S78 were sensitive to alkaline phosphatase treat-
ment, indicating that both were due to phosphorylation. To
determine whether pBid was related to cell cycle, we arrested
WT-MEFs in G1 (double thymidine block) or M (nocodazole).
pBid was significantly enriched in mitosis (Figure 2C). After
nocodazole washout, pBid disappeared synchronously with
phosphorylated histone H3 (pSer10-H3), i.e., as the cell pro-
gressed through themetaphase-anaphase transition (Figure 2D).
However, if mitotic exit following nocodazole washout was
blocked with the proteasome inhibitor MG132 (confirmed by
persistent pSer10-H3), pBid was not lost (Figure 2D).
To confirm that pBid accumulated as cells enter mitosis, WT-
MEFs were arrested in G1 and then released, with or without a
CDK1 inhibitor (RO-3306) to prevent entry into M or nocodazole
to arrest cells before mitotic exit (Figure 2E). Both pBid andFigure 1. Bid Is Required for Apoptosis following Delayed Mitotic Exit
(A) Knockdown and re-expression of Bid in human carcinoma cells. RKO cells stab
immunoblotted for human Bid (hBid) and BidYFP. Vinculin was immunoblotted a
(B) RKO and DLD1 cells expressing pVenus, pVenus-shBid, or pVenus-shBid-
collected and apoptosis quantified by immunostaining for active caspase 3. Th
experiments. Data were analyzed by ANOVA. n/s, not significant.
(C) In the left panel, RKO cells stained with Hoechst. RKO cells remained in mit
18 hr in paclitaxel. In the right panel, RKO cells treated with paclitaxel immuno
indicated by the arrow shows that active caspase 3 corresponds with loss of mi
(D) Bid/ mouse embryonic fibroblasts (MEF) were stably infected with lentivir
combinations of paclitaxel and ABT-737 for 18 hr. Apoptosis was quantified
independent experiments.H3-pS10 failed to accumulate in RO-3306-treated cells. Further-
more, the pBid that accumulated over 8 hr in cells arrested
in M by nocodazole was lost following brief treatment with
RO-3306, indicating its maintenance in mitosis required Cdk1
activity. However, as RO-3306 will cause mitotic slippage in
nocodazole-treated cells, we repeated the experiment but also
included MG-132 to maintain cyclin B levels (Figure 2F). Again,
pBid was lost upon inhibition of Cdk1, even if cyclin B degrada-
tion was inhibited. Bid phosphorylation also occurred in epithe-
lial cells and in MEFs arrested with paclitaxel or monastrol,
an Eg5 inhibitor, indicating that it was a general phenomenon
associated with mitosis (Figures S2A and S2B). Interestingly,
compromising the SAC with an aurora kinase inhibitor did not
inhibit pBid accumulation in cells arrested in M (Figure S2C).
However, Bid is probably not a direct Cdk1 target. Mouse Bid
has no consensus Cdk1 sites, although human Bid has one
possible phosphorylation site (Figure S2D). However, active
Cdk1 did not phosphorylate recombinant Bid in vitro.
These data reveal that Bid is phosphorylated during mitosis
and that pBid is lost concomitant with the metaphase to
anaphase transition.
Mouse Bid Is Phosphorylated on S66 during Mitosis
To identify the mitotic phosphorylation sites in Bid, mBidYFP
was isolated from nocodazole-treated human embryonic kidney
293T (HEK293T) cells and separated by SDS-PAGE. mBidYFP
showed the same mobility shift as seen with endogenous mBid
(cf. Figure 3A with 2C). The upper- and lower-molecular-weight
bands of mBidYFP were excised, digested with AspN, and
analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS). A peptide corresponding to mBid amino acids
59–74 from the upper band had a single phosphate group,
whereas the equivalent peptide from the lower band was un-
modified. The fragmentation spectra of this peptide indicated
the phosphate was on S66 (Figure 3B). Identical MS/MS data
were obtained with a synthetic phosphopeptide corresponding
to mBid residues 59–74 with phosphate on S66 (Figure 3C).
We did not detect any other modifications in mBidYFP from
mitotic cells. Furthermore, mBidYFP isolated from untreated
cells was not phosphorylated.
To confirm the MS data, we generated a phosphospecific
antibody to Bid S66, which detected the slower migrating form
of mBidYFP-WT (Figure 3D). We also substituted all potential
phosphorylation sites within the regulatory loop of mBidYFP
to alanine. MEFs transiently expressing these mutated proteins
were arrested by double-thymidine block or nocodazole andly expressing control pVenus, pVenus-shBid, or pVenus-shBid-mBidYFPwere
s a loading control. IB, immunoblot.
mBidYFP were left untreated or treated with paclitaxel for 18 hr. Cells were
e error bars represent SEM. Data represent the mean of three independent
osis when knockdown of Bid prevented them undergoing apoptosis following
stained for cytochrome c and active caspase 3, as well as Hoechst. The cell
tochondrial cytochrome c and pyknotic nuclei.
us expressing either BidYFP-WT or BidYFP-G94E, before being treated with
as in (B). The error bars represent SEM. Data represent the mean of three
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Figure 2. Endogenous Bid Undergoes Reversible Posttranslational Modification during Mitosis
(A) Schematic representation of mouse Bid, showing known sites of posttranslational modification within the loop between a helices 2 and 3.
(B) Endogenous Bid in MEFs migrates as multiple forms. MEFs were treated with etoposide for 1 hr and lysates analyzed by immunoblotting for Bid, with
or without alkaline phosphatase (AP) treatment. The higher-migrating form of Bid is indicated (pBid). The slower-migrating form of Bid phosphorylated in
response to etoposide is also indicated (Bid p61/p78).
(C) Lysates from MEFs arrested in either G1 or mitosis were analyzed by immunoblotting for Bid or phosphorylated histone H3 (pSer10-H3).
(D) MEFs arrested in mitosis were collected by overnight treatment with nocodazole and shaking from the dish. These cells were replated into media with or
without MG132. Lysates were collected at the indicated times and immunoblotted for Bid, cyclin B, phospho-histone H3, and calnexin.
(E) MEFs enriched in G1 were released for 8 hr into the indicated combinations of nocodazole and RO-3306. In the right lane, cells were released into nocodazole
for 8 hr and RO-3306 added for 1 hr prior to lysis. Lysates were immunoblotted for Bid and pSer10-H3.
(F) MitoticMEFswere collected by overnight treatment in nocodazole, followed by shake off, and replated in the indicated combinations of nocodazole, RO-3306,
and MG132 for 2 hr. Lysates were immunoblotted for Bid, cyclin B, phospho-histone H3, and calnexin.
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the latter divided into those that could be detached by shaking
(M) and those that remained attached to the culture dish (A)
(Figure 3E). Substitution of all the potential phosphorylation
sites other than S66 (BidYFP-S66D5) did not prevent themobility
shift in nocodazole-treated cells. Conversely, Bid containing a
substitution at S66 alone (BidYFP-S66A) showed no mobility
shift in mitosis. Furthermore, substituting S66 to aspartic acid
(BidYFP-S66D) resulted in a similar size shift as seen for phos-
phorylated Bid, even in cells in G1. Phosphorylation of Bid on
S66 was independent of the DNA-damage-induced phosphory-
lation on S61/S78 following etoposide-induced DNA damage
(Figures 3E and S2E).
The sequences of human and mouse Bid diverge within the
regulatory loop, with potential phosphorylation sites at S64,
S65, and S67 in humans (Figure 3F). Furthermore, endogenous
human Bid did not show a mobility shift when RKO or DLD1
cells were arrested in mitosis (Figure 3G). To ask if human Bid
was phosphorylated in mitosis, hBidYFP was isolated from
HEK293T cells and analyzed by LC-MS/MS. A peptide from
hBidYFP isolated from mitotic cells corresponding to amino
acids 55–74 was phosphorylated uniquely on S67 (Figure 3H).
No modifications were found in hBidYFP isolated from untreated
cells. No phosphorylation was detected by LC-MS/MS on
the putative Cdk-1 consensus site at T163 (Figure S2D), in either
untreated or nocodazole-treated cells.
These results demonstrate that Bid is phosphorylated on a
unique serine residue specifically in mitosis.
Bid-pS66 Sensitizes Cells to Apoptosis following
Delayed Mitotic Exit
To test if Bid-pS66 regulates apoptosis during mitotic arrest,
we generated stable RKO lines where endogenous hBid
was knocked down and substituted by mouse BidYFP-WT,
BidYFP-S66A, BidYFP-S66D, or BidYFP-G94E. As expression
of mBidYFP was significantly higher than endogenous hBid
using the original pVenus vector with an EF1a promoter (Fig-
ure S3A), we replaced it with an ubiquitin (Ub) promoter. This
led to expression of mBidYFP at levels comparable to endoge-
nous hBid (Figures 4A and S3B). When the RKO lines were
treated with paclitaxel for 18 hr, although BidYFP-WT rescuedFigure 3. Bid Is Phosphorylated on Serine 66 during Mitosis
(A) BidYFP was transiently expressed in HEK293T cells, which were untreated, or
by SDS-PAGE, and stained with Coomassie blue. pBid is indicated as the samp
(B) Fragmentation spectrum of the AspN-generated Bid peptide corresponding to
and also a fragment ion that demonstrates that the peptide is phosphorylated at S
other serine residues present in the peptide. Fragment ions b3 and b5 discount S
(C) Fragmentation spectrum of synthetic peptide representing mouse Bid amino
fragment ions identified in (B).
(D) Bid/MEFs expressing either BidYFP-WT or BidYFP-S66A were untreated o
andWCLs were separated by SDS-PAGE and immunoblotted for total Bid or Bid p
WT cells treated with nocodazole.
(E) MEFs transiently expressing the indicated BidYFP constructs were arrested
remaining cells attached to the dish were also collected (A). Lysates were analyz
(F) Comparison of the amino acids sequences from mouse (top) and human (bot
are indicated.
(G) Human Bid does not show a shift in mobility by SDS-PAGE. DLD1 and RKO cel
for endogenous Bid.
(H) Fragmentation spectrum of the AspN-generated peptide corresponding t
nocodazole-treated HEK293T cells. The data include diagnostic ions showing hB
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dYFP-S66A nor BidYFP-G94E BH3 mutant were able to restore
the response (Figures 4B–4D). Notably, BidYFP-S66D was not a
functional phospho-mimetic and was also unable to restore the
response. Similar results were obtained in Bid/MEFs stably
expressing Ub-promoter-driven BidYFP-WT, BidYFP-66A, and
BidYFP-G94E (Figure 4E). To ask if phosphorylation of human
Bid on S67 had the same role, we generated RKO cells where
endogenous hBid was knocked down and hBidYFP-WT or
hBidYFP-S67A expressed (Figure 4A). hBidYFP-WT rescued
paclitaxel-induced apoptosis in Bid knockdown RKO cells, but
hBidYFP-S67A did not (Figures 4F and S4A).
To determine whether the proapoptotic role of Bid during
mitosis was seen when cells were treated with other antimitotic
drugs, we treated RKO cells with monastrol. These cells also
displayed Bid-S66-phosphorylation-dependent apoptosis (Fig-
ure 4G), although the level of cell death was much lower than
with paclitaxel. However, RKO cells weremore prone to slippage
in monastrol than in paclitaxel (compare Figures S4A and S4B).
Lastly, to determine whether knockdown of Bid altered the
general sensitivity of cells to apoptosis, we treated RKO
cells with etoposide. There was no effect of Bid knockdown, or
expression of mBidYFP-WT or mBidYFP-S66A, on etoposide-
induced apoptosis (Figure S4C).
These data reveal that apoptotic sensitivity of both MEFs
and human colon carcinoma cells to mitotic arrest requires Bid
to be phosphorylated on S66.
Bid-pS66 Controls Mitotic Apoptosis by Sensitizing
the Mitochondrial Pathway
To understand how Bid S66 phosphorylation promotes
apoptosis during delayed mitosis, we initially examined whether
it influences the subcellular localization of Bid. However, both
untreated and paclitaxel-treated RKO cells showed a mitochon-
drial distribution of stably expressed BidYFP-WT, BidYFP-S66A,
and BidYFP-G94E, indicating that neither phosphorylation,
nor a functional BH3 domain, were required for localization
(Figure S5A). Consequently, we hypothesized that Bid-pS66
altered the interactions of Bid with antiapoptotic Bcl-2 proteins
to increase mitochondrial priming during mitosis. To test this,treated with nocodazole. BidYFP was isolated on GFP-trap agarose, separated
le isolated from nocodazole-treated cells.
amino acids 59–74. The data include diagnostic ions that identify the peptide
er66 (y9). No fragment ions were observed supporting phosphorylation at any
61 phosphorylation.
acids 59–74, phosphorylated on S66. This peptide shows the same diagnostic
r treated with nocodazole and precipitated on GFP-Trap agarose. Precipitates
hospho-S66. A phospho-S66-positive band was only detected in the BidYFP-
in either G1 or mitosis. Mitotic cells were collected by shaking (M) and the
ed by immunoblotting for Bid.
tom) Bid in the regulatory loop. The regions of divergence around mouse S66
ls were treated with paclitaxel for 18 hr and lysates analyzed by immunoblotting
o amino acids 55–74 from hBid-YFP, isolated on GFP-Trap agarose from
id-YFP is phosphorylated uniquely on S67.
(legend on next page)
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we inhibited antiapoptotic Bcl-2 protein function with the BH3
mimetic, ABT-737. ABT-737 alone did not induce apoptosis in
either WT- or Bid/MEFs. However, whereas ABT-737 sensi-
tized WT-MEFs to apoptosis following treatment with paclitaxel,
it had no effect on the resistance of Bid/MEFs, suggesting
that apoptotic priming in mitosis requires Bid (Figure 5A). We
then asked if the RKO lines in which hBid had been replaced
with BidYFP-WT or BidYFP-S66A could be sensitized to
paclitaxel by ABT-737. Again, ABT-737 alone did not increase
apoptosis in any of the RKO lines. However, ABT-737 sensitized
both the parental RKO cells and cells expressing BidYFP-WT to
paclitaxel, but not those in which only endogenous hBid was
knocked down (Figure 5B). Interestingly, ABT-737 did sensitize
the BidYFP-S66A cells to paclitaxel, and apoptosis in these cells
was rescued to almost the same level as parental and BidYFP-
WT cells. This suggests that full-length Bid has a basal proapo-
ptotic activity that is increased by phosphorylation on S66.
Lastly, we examined the paclitaxel-resistant DLD1 cells.
Paclitaxel resistance was not due to defective Bid phosphoryla-
tion, as mBidYFP-WT was phosphorylated on S66 in mitotic
DLD1 cells (Figure 5C). Furthermore, when mitotic RKO and
DLD1 cells were compared, similar proportions of phospho-
rylated mBidYFP were seen (Figure 5D). Death during arrested
mitosis has been proposed to be initiated by the degradation
of Mcl-1 (Harley et al., 2010; Wertz et al., 2011). Surprisingly,
both DLD1 and Bid/MEFs expressed less Mcl-1 than the
paclitaxel-sensitive RKO cells (Figure S5B). However, all the
lines showed loss of Mcl-1 during mitotic arrest. Consequently,
we asked if paclitaxel sensitivity might be achieved in DLD1 cells
with BH3 mimetics. DLD1 cells were not sensitive to ABT-737
alone, similar to the RKO and MEFs, and DLD1 cells in paclitaxel
tend to exit mitosis by slippage (Figures S1A and 5F). However,
ABT-737 dramatically sensitized DLD1 cells to apoptosis in
paclitaxel, quantified by active caspase 3 (Figures 5E and 5F).
We generated DLD1 cells where endogenous Bid was knocked
down and either hBidYFP-WT or hBidYFP-S67Awere expressed
(Figure S5C). When these were treated with paclitaxel and
ABT-737, the same sensitization was seen as with RKO cells
(compare Figures 5B and S5D). These data suggest that
paclitaxel-resistant DLD1 cells become primed by Bid phos-
phorylation just like RKO cells but tend to undergo slippage
before MOMP can be initiated.Figure 4. Bid Phosphorylation on Serine 66 Sensitizes Cells to Apopto
(A) RKO cells stably infectedwith pVenus, pVenus-shBid, or pVenus-shBid coexpr
under the ubiquitin promoter were analyzed by immunoblotting with an antibody th
a loading control. Endogenous human Bid is only present in the control cells.
(B) The control RKO lines and those expressing mouse BidYFP variants were u
immunoblotting for Bid and active caspase 3. Erk was a loading control. Note the s
(C) The RKO lines from (A), untreated or treated with 1 mM paclitaxel for 18 hr, w
represent the mean of three independent experiments. The error bars represent
(D) Images of the paclitaxel-treated RKO cell lines from (C), immunostained for a
(E) Bid/MEFs, infected with the indicated pVenus lentiviruses, were left untreate
represent the mean of three independent experiments. The error bars represent
(F) RKO cells infected with the indicated lentiviruses expressing human Bid or
responses to those expressing the mouse BidYFP. The data represent the mean
analyzed by ANOVA.
(G) The indicated RKO lines, untreated or treated with monastrol for 18 hr, were im
the mean of three independent experiments. The error bars represent SEM. Data
668 Cell Reports 7, 661–671, May 8, 2014 ª2014 The AuthorsTogether, these results show that mitochondrial priming for
apoptosis via Bid phosphorylation is a general event in mitosis,
even in cells that are otherwise resistant to mitotic-arrest-
induced death.
DISCUSSION
As cells progress through mitosis, they initiate two timers, each
driven by the proteolysis of a regulator (Topham and Taylor,
2013). Thus, loss of cyclin B leads to mitotic slippage (Brito
and Rieder, 2006), whereas degradation of Mcl-1 results in
MOMP (Harley et al., 2010; Wertz et al., 2011). Normally, inacti-
vation of the SAC following spindle attachment leads to rapid
cyclin B degradation and mitotic exit before Mcl-1 loss reaches
the point where death occurs. However, although mitotic cells
are sensitive to loss or inhibition of antiapoptotic Bcl-2 proteins,
outside of mitosis they are not. The relative dependence of
cells on antiapoptotic Bcl-2 proteins is termed mitochondrial
priming and changes according to the milieu of Bcl-2 proteins
on the outer mitochondrial membrane (OMM) (Del Gaizo Moore
and Letai, 2013; Schellenberg et al., 2013). Increased priming
results in a cell becoming more dependent upon antiapoptotic
Bcl-2 proteins to suppress MOMP, seen by their sensitivity to
BH3 mimetics (Certo et al., 2006; Deng et al., 2007; Llambi
et al., 2011). Our data presented here indicate that Bid S66
phosphorylation sensitizes cells to apoptosis, making them
dependent upon antiapoptotic Bcl-2 proteins as they enter
mitosis.
Bid can be phosphorylated on several residues with the regu-
latory loop between helices 2 and 3 (Degli Esposti et al., 2003;
Desagher et al., 2001; Kamer et al., 2005; Zinkel et al., 2005).
How phosphorylation on S66 alters Bid function is unclear at
present, but we found no evidence that it alters its susceptibility
to cleavage by caspase 8 (P.W., J.L., and A.P.G., unpublished
data). Indeed, we found that the noncleavable BidD59E
mutant was both phosphorylated in mitosis and restored pacli-
taxel sensitivity to RKO cells following endogenous hBid
knockdown.
Loss of endogenous Bid did not completely desensitize
RKO cells to apoptosis during mitotic arrest (Figures 1B and 4).
Whereas this may be due to incomplete knockdown, it was
notable that re-expression of the nonphosphorylatable S66Asis during Mitotic Arrest
essing the indicatedmouse (left panel) and human (right panel) BidYFP variants
at recognizes both human andmouse Bid. Immunoblotting for Erk was used as
ntreated or treated with 1 mM paclitaxel for 18 hr. Lysates were analyzed by
hift inmobility of BidYFP-WT andBidYFP-G94E in paclitaxel-treated RKO cells.
ere immunostained for active caspase 3 and apoptosis quantified. The data
SEM. Data were analyzed by ANOVA.
ctive caspase 3. Nuclei were stained with Hoechst.
d or treated with 1 mMpaclitaxel. Apoptosis was quantified as above. The data
SEM. Data were analyzed by ANOVA.
human BidS67A were treated with paclitaxel as in (C). Cells showed similar
of three independent experiments. The error bars represent SEM. Data were
munostained for active caspase 3 and apoptosis quantified. The data represent
were analyzed by ANOVA.
(legend on next page)
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or BH3 domain mutants resulted in further suppression of
apoptosis. Consequently, we think that phosphorylation on
S66 might bring about a conformational change to alter BH3
domain availability, altering how Bid interacts with multidomain
Bcl-2 proteins, and might explain a dominant-negative effect
of nonfunctional Bid at the mitochondria. Furthermore, the
observation that BidYFP-S66A cells could be sensitized to
apoptosis with ABT-737, whereas the Bid deficient or BidYFP-
G94E cells could not, suggests that phosphorylation increases
a basal proapoptotic activity inherent to full-length Bid. Possible
mechanisms are currently under investigation.
Resistance to antimitotics in cancer can occur by either
resistance to MOMP or increased mitotic slippage. Maintaining
mitotic arrest for longer allows resistant cells to reach the
threshold for MOMP (Huang et al., 2009). Similarly, BH3
mimetics such as navitoclax (ABT-263), the orally active variant
of ABT-737, accelerate apoptosis during mitotic arrest (Shi
et al., 2011). As the paclitaxel-resistant DLD1 cells still under-
went apoptotic priming by Bid phosphorylation, they could be
sensitized to mitotic-arrest-induced apoptosis by ABT-737,
without directly targeting the SAC. Thus, reducing the threshold
for MOMP using BH3 mimetics achieves the same goal as
prolonging arrest in mitosis.
In summary, we have found that phosphorylation of Bid
primes mitochondria for apoptosis and makes a cell dependent
upon antiapoptotic Bcl-2 proteins. At anaphase, as soon as
the cell has satisfied the requirements to exit mitosis, Bid
phosphorylation is lost and mitochondrial priming restored to
interphase levels. It is also interesting to note that Bid-deficient
mice spontaneously develop myeloid tumors with multiple
chromosomal abnormalities, which is expected if loss of Bid
function allows cells to survive aberrant mitosis (Zinkel et al.,
2003). Furthermore, ATM/ATR phosphorylation of Bid is required
for an S phase checkpoint (Kamer et al., 2005; Zinkel et al., 2005)
and is involved in the DNA damage response in vivo (Biswas
et al., 2013; Maryanovich et al., 2012). Together with those
studies, our results support a role for Bid as a sentinel of genomic
integrity during the cell cycle.EXPERIMENTAL PROCEDURES
Detailed descriptions of reagents, cell culture, immunofluorescent imaging,
cell proliferation and apoptosis assays, and immunoblotting are provided in
the Supplemental Experimental Procedures.Figure 5. Bid Phosphorylation on Serine 66 Increases Mitochondrial P
(A) Wild-type and Bid/MEFs were treated for 18 hr with the indicated combi
immunostaining for active caspase 3. Data represent the mean of three indepen
(B) RKO cells infected with control pVenus, pVenus-shBid, pVenus-shBid-BidYFP
5 mM ABT-737, 1 mM paclitaxel, or both ABT-737 and paclitaxel. Apoptosis was q
three independent experiments. The error bars represent SEM.
(C) DLD1 cells infected with pVenus, pVenus-shBid, pVenus-shBid-BidYFP-WT,
overnight. Lysates were immunoblotted for Bid.
(D) DLD1 and RKO cells, control or expressing mouse BidYFP-WT, were arrested
immunoblotted for Bid. Quantification of the pBid/Bid ratios using Odyssey-base
(E) DLD1 cells expressing endogenous Bid were treated with the indicated comb
apoptosis quantified. Data represent the mean of three independent experiment
(F). Representative images from (E).
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BidYFP expression and endogenous Bid knockdown were achieved using
the pVenus lentiviral transfer vector, a modified version of pLVTHM in which
a multiple cloning site was introduced downstream of the EF1a promoter (a
gift from Didier Trono). The hBid shRNA hairpin was introduced downstream
of the H1 promoter (target sequence AAGAAGACATCATCCGGAATA). BidYFP
was amplified by PCR and inserted in the multiple cloning site regulated by
the EF1a promoter. Amino acid substitutions were introduced into the Bid
sequence by oligonucleotide-directed mutagenesis. To reduce BidYFP
expression, the ubiquitin promoter was PCR amplified from p199-UbTAzeo
and cloned in place of the EF1a promoter. To re-express hBid in the shBid
knockdown cells, the target sequence for the shRNA was mutated in hBid
to AAGAGGATATAATACGGAATA (substitutions are underlined). The amino
acid sequence of the expressed protein was unaltered.Cell Cycle Arrest and Drug Treatments
Cells were arrested in G1 by double thymidine block. Cells were incubated
overnight with 2.5 mM thymidine and released from the block in medium
without thymidine for 8 hr followed by another overnight treatment with
2.5 mM thymidine. To arrest cells in mitosis, G1-arrested cells were rinsed
and incubated in the presence of 200 ng/ml nocodazole for 8 hr or unsyn-
chronized cells were treated with nocodazole overnight. Mitotic cells were
collected by shake off. In mitotic release experiments, cells were arrested
in mitosis by an overnight incubation in nocodazole (200 ng/ml) and then
incubated in the normal growth medium lacking nocodazole for various times.
The cdk1 inhibitors RO-3306 (20 mM) and RO-31-8220 (10 mM) were used
to arrest cells at G2/M prior to entry into mitosis. The aurora A inhibitor,
ZM447439, was used at 2 mM. Mitotic exit was blocked with 10 mM MG132
to prevent cyclin B degradation.Mass Spectrometry Analysis of Bid Phosphorylation
BidYFP was isolated from transfected HEK293T cells lysed in Radio-
Immunoprecipitation Assay buffer (50 mM Tris Cl [pH 7.6], 150 mM NaCl,
1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 2 mM EDTA,
10 mM NaF, 1 mM Na3VO4, protease inhibitors) by precipitation on GFP-
Trap agarose (ChromoTek). BidYFP was separated by SDS-PAGE, stained
with Coomasie blue, and cut out from the gel. Excised gel bands were
reduced, alkylated with iodoacetamide, and digested overnight with Asp-N
(Sigma-Aldrich). Mouse sample digests were analyzed by multiple reaction
monitoring (MRM)-LC-MS/MS using a nanoAcquity (Waters) coupled to a
4000 Q-Trap (Applied Biosystems). The mass spectrometer was employed
to detect (by MRM) a neutral loss from the predicted m/z values for the phos-
phorylated Bid peptides of interest. Human Bid samples were analyzed by
LC-MS/MS using an UltiMate 3000 Rapid Separation LC (RSLC; Dionex)
coupled to an Orbitrap Elite (Thermo Fisher Scientific) mass spectrometer.
Peptide mixtures were separated by liquid chromatography and selected for
fragmentation by MRM initiation (4000 Q-Trap) or automatically via data-
dependent analysis (Orbitrap Elite). Data produced were searched using
Mascot (Matrix Science UK), against the Uniprot database. Phosphorylation
was included in the search parameters as a variable modification. The Mascotriming in Mitotic Cells
nations of ABT-737, paclitaxel, and etoposide. Apoptosis was quantified by
dent experiments. The error bars represent SEM.
-WT, or pVenus-shBid-BidYFP-S66A were untreated or treated for 18 hr with
uantified by immunostaining for active caspase 3. Data represent the mean of
or pVenus-shBid-BidYFP-S66A were left untreated or treated with nocodazole
overnight in nocodazole and mitotic cells collected by shaking. Lysates were
d imaging showed no difference between the cell types.
inations of drugs for 18 hr. Cells were immunostained for active caspase 3 and
s and analyzed by ANOVA. The error bars represent SEM.
output was subsequently validated using Scaffold (Proteome Software). The
product ion spectra were also assessed manually.
Statistical Analysis
Quantitative data were analyzed by either one-way or two-way ANOVA using
Bonferroni’s multiple comparison test where indicated (GraphPad Prism).
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